Headlines

Merck (MRK) announces the US FDA has approved LIPFENDRA tablets 20 mg as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including HeFH; Phase 3 trials cut LDL-C between 56-59%

Newsquawk Staff ·

Merck (MRK) announces the US FDA has approved LIPFENDRA tablets 20 mg as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including HeFH; Phase 3 trials cut LDL-C between 56-59%.

Related headlines